Celldex May Have Best Efficacy In Chronic Spontaneous Urticaria
Sanofi Also Succeeds With BTKi In Phase II
Looking to treat patients with CSU uncontrolled by Xolair, Celldex’s KIT binder barzolvolimab shows strong disease activity reduction at 12 weeks in Phase II. Sanofi’s BTK inhibitor rilzabrutinib also showed efficacy in CSU.
